Few biopharma risers stand out at the half year
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
First-quarter biotech risers work hard for the win
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
Digging into biopharma’s big buyout areas
Cancer, rare diseases and neurology targets account for a big chunk of biopharma's buyouts, with interest showing no sign of waning.
Rare disease and neurology takeouts tick higher
Biopharma's growing appetite for higher-risk areas prompts a shift in dealmaking strategies, our latest deep dive into M&A data finds.
The year of the small buyout
Biopharma takeouts in the $1-5bn range jumped in 2021, as rising valuations made their mark.
